Martin-Willett, R.; Skrzynski, C.J.; Taylor, E.M.; Sempio, C.; Klawitter, J.; Bidwell, L.C.
The Interplay of Exogenous Cannabinoid Use on Anandamide and 2-Arachidonoylglycerol in Anxiety: Results from a Quasi-Experimental Ad Libitum Study. Pharmaceuticals 2024, 17, 1335.
https://doi.org/10.3390/ph17101335
AMA Style
Martin-Willett R, Skrzynski CJ, Taylor EM, Sempio C, Klawitter J, Bidwell LC.
The Interplay of Exogenous Cannabinoid Use on Anandamide and 2-Arachidonoylglycerol in Anxiety: Results from a Quasi-Experimental Ad Libitum Study. Pharmaceuticals. 2024; 17(10):1335.
https://doi.org/10.3390/ph17101335
Chicago/Turabian Style
Martin-Willett, Renée, Carillon J. Skrzynski, Ethan M. Taylor, Cristina Sempio, Jost Klawitter, and L. Cinnamon Bidwell.
2024. "The Interplay of Exogenous Cannabinoid Use on Anandamide and 2-Arachidonoylglycerol in Anxiety: Results from a Quasi-Experimental Ad Libitum Study" Pharmaceuticals 17, no. 10: 1335.
https://doi.org/10.3390/ph17101335
APA Style
Martin-Willett, R., Skrzynski, C. J., Taylor, E. M., Sempio, C., Klawitter, J., & Bidwell, L. C.
(2024). The Interplay of Exogenous Cannabinoid Use on Anandamide and 2-Arachidonoylglycerol in Anxiety: Results from a Quasi-Experimental Ad Libitum Study. Pharmaceuticals, 17(10), 1335.
https://doi.org/10.3390/ph17101335
